Strides gains an FDA approval
BUFFALO GROVE -- Akorn-Strides Friday announced the approval of an ANDA for Rifampin for injection USP, 600 mg/vial. This is the first lyophilized injectable product approval for the joint venture. Akorn-Strides is a Joint Venture that was formed in 2005 by Akorn Inc. and Strides Arcolab Ltd. The primary mission for the joint venture is to develop liquid, lyophilized and dry powder formulations of generic injectable products targeting several therapeutic markets with a major focus on anti-infectives and analgesics.
Article Comments
Guidelines: Keep it civil and on topic; no profanity, vulgarity, slurs or personal attacks. People who harass others or joke about tragedies will be blocked.
If a comment violates these standards or our terms of service, click the "flag" link in the lower-right corner of the comment box. To find our more, read our FAQ.